Stock Financial Ratios

ARDM / Aradigm Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price1.30
Volume70,800.00
Market Cap ($M)62.36
Enterprise Value ($M)50.04
Book Value ($M)0.99
Book Value / Share0.07
Price / Book-2.10
NCAV ($M)0.73
NCAV / Share1.30
Price / NCAV-2.06
Income Statement (mra) ($M)
Revenue0.20
EBITDA-30.02
Net Income-32.94
Balance Sheet (mrq) ($M)
Cash & Equivalents12.59
Cash / Share0.85
Assets13.96
Liabilities23.13
Quick Ratio4.24
Current Ratio4.24
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-33.37
Return on Assets (ROA)-1.31
Return on Equity (ROE)-33.37
Identifiers and Descriptors
CUSIP038505400
Central Index Key (CIK)1013238
Industry Groups
SIC 3845 - Electromedical and Electrotherapeutic Apparatus
Other Related CUSIPS
038505301
Share Statistics
Preferred Stock Shares Outstanding0
Common Stock Shares Outstanding14,951,089
Common Shares Outstanding14,951,089
Scoring Models
Piotroski F-Score0.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Minority Interest Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Assets Per Share0.93
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Accounts Payable Per Share0.00
Assets Non Current Per Share0.00
Inventory Per Share0.00
Cash And Equivalents Per Share0.84
Retained Earnings Per Share0.00
Liabilities And Stock Equity Per Share0.00
Cash Per Share0.85
Assets Other Non Current Per Share0.00
Liabilities Per Share1.56
Inventory Work In Progress Per Share0.00
Goodwill Per Share0.00
Property Plant And Equipment Net Per Share0.00
Additional Paid In Capital Per Share0.00
Liabilities Current Per Share0.00
Debt Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Equity Per Share-0.61
Assets Current Per Share0.91
Assets Other Current Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Intangibles Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00

Related News Stories

Aradigm: Points Of Discussion

2018-02-02 seekingalpha
As some items are still developing (which may or may not bear fruit), this isn't going to be a full-fledged article. But, here are a six quick thoughts for Aradigm (ARDM) investors to consider. (132-30)

Biotech Forum Daily Digest For January 31st

2018-01-31 seekingalpha
Amazon, JPMorgan and Berkshire Hathaway announce the launch of a new healthcare company to reduce healthcare costs for their employees. (249-0)

Your Daily Pharma Scoop: Sanofi To Acquire Ablynx, PTC Therapeutics Announces Data, Lutathera Approved

2018-01-30 seekingalpha
Today we will discuss Sanofi’s (SNY) takeover offer for Belgian biotech Ablynx (OTCPK:ABLYF). Ablyx had earlier this month rejected a hostile takeover offer from Novo Nordisk (NVO), noting that euro 30.50 per share offer undervalued the company. We had discussed in a recent article that the Novo offer undervalued the company and that a higher offer from the Danish biopharma was likely. However, before that could happen, Sanofi offered significant premium to Ablynx and the French biopharma’s offer has already been accepted. (235-2)

U.S. Biotech/Pharma Sector Daily Observations Letter: January 29, 2018

2018-01-30 seekingalpha
Small pullback (as expected) in the U.S. equity indexes (advances: declines= 20%: 70%) but a new high is likely before a meaningful pullback. Today's pullback in equities appears related to a selloff in bonds (due to rising yields). Support for S&P 500 is at 2830-2840. (15-0)

Biotech Analysis Central Pharma News: Aradigm's FDA Rejection, Sanofi's Extra Buy, Theravance And Mylan's FDA Push

2018-01-30 seekingalpha
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. (96-0)

CUSIP: 038505400